ARTICLE | Company News
Antisoma, Institute of Cancer Research deal
October 13, 2008 7:00 AM UTC
Antisoma received worldwide, exclusive rights to develop and commercialize the institute's inhibitors of protein phosphatase magnesium-dependent 1 delta (PPM1D, WIP1) to treat cancer. The company an...